Haderlein M - Search Results

1

Extramedullary plasmacytoma: Tumor occurrence and therapeutic concepts-A follow-up.

Holler A, Cicha I, Eckstein M, Haderlein M, Pöttler M, Rappl A, Iro H, Alexiou C. Holler A, et al. Among authors: haderlein m. Cancer Med. 2022 Dec;11(24):4743-4755. doi: 10.1002/cam4.4816. Epub 2022 May 16. Cancer Med. 2022. PMID: 35578404 Free PMC article. Review.

2

Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: what are the best predictors of remission and prognosis?

Semrau S, Haderlein M, Schmidt D, Lell M, Wolf W, Waldfahrer F, Uder M, Iro H, Kuwert T, Fietkau R. Semrau S, et al. Among authors: haderlein m. Cancer. 2015 Apr 15;121(8):1214-22. doi: 10.1002/cncr.29188. Epub 2014 Dec 23. Cancer. 2015. PMID: 25537381 Free article.

3

High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype.

Haderlein M, Scherl C, Semrau S, Lettmaier S, Uter W, Neukam FW, Iro H, Agaimy A, Fietkau R. Haderlein M, et al. Head Neck. 2016 Apr;38 Suppl 1:E2041-8. doi: 10.1002/hed.24375. Epub 2016 Feb 3. Head Neck. 2016. PMID: 26841273

4

Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.

Haderlein M, Scherl C, Semrau S, Lettmaier S, Hecht M, Erber R, Iro H, Fietkau R, Agaimy A. Haderlein M, et al. Strahlenther Onkol. 2017 Nov;193(11):961-970. doi: 10.1007/s00066-017-1196-8. Epub 2017 Aug 21. Strahlenther Onkol. 2017. PMID: 28828496 English.

5

Is there a patient population with squamous cell carcinoma of the head and neck region who might benefit from de-intensification of postoperative radiotherapy? : A monocentric retrospective analysis of a previously defined low-risk patient population treated with standard-of-care radiotherapy.

Onbasi Y, Lettmaier S, Hecht M, Semrau S, Iro H, Kesting M, Fietkau R, Haderlein M. Onbasi Y, et al. Among authors: haderlein m. Strahlenther Onkol. 2019 Jun;195(6):482-495. doi: 10.1007/s00066-018-1415-y. Epub 2019 Jan 4. Strahlenther Onkol. 2019. PMID: 30610355 English.

6

Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands.

Haller F, Bieg M, Will R, Körner C, Weichenhan D, Bott A, Ishaque N, Lutsik P, Moskalev EA, Mueller SK, Bähr M, Woerner A, Kaiser B, Scherl C, Haderlein M, Kleinheinz K, Fietkau R, Iro H, Eils R, Hartmann A, Plass C, Wiemann S, Agaimy A. Haller F, et al. Among authors: haderlein m. Nat Commun. 2019 Jan 21;10(1):368. doi: 10.1038/s41467-018-08069-x. Nat Commun. 2019. PMID: 30664630 Free PMC article.

7

Salivary gland carcinoma (SGC) with perineural spread and/or positive resection margin - high locoregional control rates after photon (chemo) radiotherapy - experience from a monocentric analysis.

Haderlein M, Scherl C, Semrau S, Lettmaier S, Hecht M, Putz F, Iro H, Agaimy A, Fietkau R. Haderlein M, et al. Radiat Oncol. 2019 Apr 23;14(1):68. doi: 10.1186/s13014-019-1260-x. Radiat Oncol. 2019. PMID: 31014362 Free PMC article.

8

Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

Scherl C, Haderlein M, Agaimy A, Mantsopoulos K, Koch M, Traxdorf M, Fietkau R, Grundtner P, Iro H. Scherl C, et al. Among authors: haderlein m. Strahlenther Onkol. 2019 Dec;195(12):1050-1059. doi: 10.1007/s00066-019-01499-6. Epub 2019 Jul 26. Strahlenther Onkol. 2019. PMID: 31350567 English.

9

Single-cycle induction chemotherapy before chemoradiotherapy or surgery in functionally inoperable head and neck squamous cell carcinoma: 10-year results.

Breheret M, Lubgan D, Haderlein M, Hecht M, Traxdorf M, Schmidt D, Müller S, Kitzsteiner C, Kuwert T, Iro H, Fietkau R, Semrau S. Breheret M, et al. Among authors: haderlein m. Eur Arch Otorhinolaryngol. 2020 Jan;277(1):245-254. doi: 10.1007/s00405-019-05665-5. Epub 2019 Oct 3. Eur Arch Otorhinolaryngol. 2020. PMID: 31583430

10

Classification of three prognostically different groups of head and neck cancer patients based on their metabolic response to induction chemotherapy (IC-1).

Semrau S, Schmidt D, Hecht M, Haderlein M, Kitzsteiner C, Müller S, Traxdorf M, Agaimy A, Iro H, Kuwert T, Fietkau R. Semrau S, et al. Among authors: haderlein m. Oral Oncol. 2020 Jan;100:104479. doi: 10.1016/j.oraloncology.2019.104479. Epub 2019 Nov 28. Oral Oncol. 2020. PMID: 31786390

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

53 results

Search Page